Simplex Trading
TVTX icon

Simplex Trading’s Travere Therapeutics TVTX Stock Holding History

Simplex Trading’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.02M Sell
101,600
-101,600
-50% -$3.04M ﹤0.01% 1500
2025
Q4 		$7.76M Sell
203,200
-4,300
-2% -$140K ﹤0.01% 1010
2025
Q3 		$4.96M Buy
207,500
+95,600
+85% +$1.8M ﹤0.01% 1464
2025
Q2 		$1.66M Buy
111,900
+30,500
+37% +$506K ﹤0.01% 2279
2025
Q1 		$1.46M Buy
81,400
+30,800
+61% +$625K ﹤0.01% 2343
2024
Q4 		$881K Buy
50,600
+11,800
+30% +$209K ﹤0.01% 2967
2024
Q3 		$542K Buy
38,800
+3,600
+10% +$37.5K ﹤0.01% 3506
2024
Q2 		$289K Buy
35,200
+16,100
+84% +$108K ﹤0.01% 4284
2024
Q1 		$147K Sell
19,100
-28,500
-60% -$240K ﹤0.01% 5176
2023
Q4 		$427K Sell
47,600
-22,100
-32% -$161K ﹤0.01% 3863
2023
Q3 		$623K Buy
69,700
+66,200
+1,891% +$934K ﹤0.01% 3172
2023
Q2 		$53K Sell
3,500
-3,600
-51% -$65.5K ﹤0.01% 5802
2023
Q1 		$159K Buy
7,100
+4,400
+163% +$93.5K ﹤0.01% 4598
2022
Q4 		$56K Sell
2,700
-17,100
-86% -$362K ﹤0.01% 5739
2022
Q3 		$487K Sell
19,800
-11,300
-36% -$292K ﹤0.01% 3506
2022
Q2 		$753K Buy
31,100
+28,300
+1,011% +$712K ﹤0.01% 2950
2022
Q1 		$72K Sell
2,800
-300
-10% -$7.96K ﹤0.01% 6624
2021
Q4 		$96K Sell
3,100
-100
-3% -$2.82K ﹤0.01% 6317
2021
Q3 		$49K Hold
3,200
– – ﹤0.01% 7529
2021
Q2 		$46K Buy
3,200
+3,010
+1,584% +$59.4K ﹤0.01% 7750
2021
Q1 		$474K Buy
190
+172
+956% +$4.75K ﹤0.01% 3456
2020
Q4 		$49K Sell
18
-65
-78% -$1.52K ﹤0.01% 6208
2020
Q3 		$153K Buy
+83
New +$1.61K ﹤0.01% 4443
2020
Q2 		– Sell
-454
Closed -$662K – 8383
2020
Q1 		$662K Buy
454
+445
+4,944% +$6.7K ﹤0.01% 2303
2019
Q4 		$12K Sell
9
-40
-82% -$511 ﹤0.01% 6300
2019
Q3 		$56K Buy
49
+8
+20% +$132 ﹤0.01% 4913
2019
Q2 		$82K Sell
41
-19
-32% -$375 ﹤0.01% 4395
2019
Q1 		$135K Buy
60
+19
+46% +$420 ﹤0.01% 4028
2018
Q4 		$92K Sell
41
-327
-89% -$8.13K ﹤0.01% 3932
2018
Q3 		$1.06M Buy
368
+367
+36,700% +$10.5K ﹤0.01% 1829
2018
Q2 		$2K Sell
1
-37
-97% -$985 ﹤0.01% 7059
2018
Q1 		$1K Sell
38
-17
-31% -$405 ﹤0.01% 5796
2017
Q4 		$3K Sell
55
-53
-49% -$1.21K ﹤0.01% 4994
2017
Q3 		$14K Buy
108
+44
+69% +$969 ﹤0.01% 3502
2017
Q2 		$7K Sell
64
-31
-33% -$562 ﹤0.01% 4330
2017
Q1 		$12K Sell
95
-68
-42% -$1.33K ﹤0.01% 3816
2016
Q4 		$47K Buy
163
+71
+77% +$1.45K ﹤0.01% 2220
2016
Q3 		$41K Buy
92
+48
+109% +$914 ﹤0.01% 2276
2016
Q2 		$12K Sell
44
-37
-46% -$599 ﹤0.01% 3445
2016
Q1 		$4K Buy
81
+35
+76% +$531 ﹤0.01% 4309
2015
Q4 		$2K Sell
46
-182
-80% -$3.64K ﹤0.01% 4603
2015
Q3 		$18K Buy
228
+188
+470% +$5.57K ﹤0.01% 2919
2015
Q2 		$8K Sell
40
-275
-87% -$7.53K ﹤0.01% 3284
2015
Q1 		$152K Buy
315
+268
+570% +$4.09K 0.02% 848
2014
Q4 		$5K Buy
+47
New +$486 ﹤0.01% 3124

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Simplex Trading's TVTX Position: Q4 2025 in Review

Simplex Trading sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 51,241 shares — an estimated $1.67M sold.

Simplex Trading first reported a position in TVTX in Q4 2014 and held it in 26 quarters. The position peaked at $1.22M in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Simplex Trading reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 51,241 Travere Therapeutics shares in Q4 2025, an estimated $1.67M.
  • Simplex Trading first reported a position in Travere Therapeutics in Q4 2014 and held it in 26 quarters.
  • Simplex Trading's Travere Therapeutics position peaked at $1.22M in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.